IP Library Granted Patent US 10,383,848
Granted Patent B2
US 10,383,848 · App. 15/669,289 · Granted Aug 20, 2019

Indole-based therapeutics

Inventors: Jeffrey North (Omaha, NE); Mary C. Jackson (Fort Collins, CO)
Assignees: Creighton University; Colorado State University Research Foundation
A61K31/404A61K31/166A61K31/02G01N27/447
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,383,848
App. No.
15/669,289
Granted
Aug 20, 2019
Kind
B2
Abstract

Provided herein are indole-2-carboxamide compounds useful for the treatment of non-tuberculosis bacterial infections. Exemplary compounds provided herein are useful for the treatment of non-tuberculosis mycobacterial infections. Methods for preparing the indole-2-carboxamide compounds are also provided.

Claims (13)

1. A method of treating a non-tuberculosis mycobacterial infection in a subject in need thereof, comprising identifying the subject as having a non-tuberculosis mycobacterial infection, and administering to the subject a therapeutically effective amount of a compound

selected from the group consisting of:

or a pharmaceutically acceptable salt thereof;

wherein the non-tuberculosis mycobacterium is selected from the group consisting of M abscessus, M. massiliense, M. bolletii, M. chelonae , and M. avium.

2. The method of claim 1 , wherein the non-tuberculosis mycobacterial infection is a hospital acquired mycobacterial infection.

3. The method of claim 1 , wherein the subject is further infected with a pathogen selected from Pseudomonas aeruginosa and Staphylococcus aureus , or a combination thereof.

4. The method of claim 1 , wherein the subject has been identified as having a lung disease.

5. The method of claim 4 , wherein the lung disease is selected from the group consisting of cystic fibrosis, bronchiectasis, emphysema, and chronic obstructive pulmonary disease, and bronchiectasis.

6. The method of claim 1 , wherein the subject is a pediatric subject.

7. The method of claim 1 , wherein the compound is selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

8. The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

Assignments (3)
CONFIRMATORY LICENSE Recorded Mar 5, 2018
From: COLORADO STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045487/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2018
From: NORTH, JEFFREY
To: CREIGHTON UNIVERSITY
Reel/Frame 044931/0552 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2018
From: JACKSON, MARY C.
To: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
Reel/Frame 044931/0711 →
Continuity (2)
Provisional Application 62370931 · Aug 4, 2016
Related Publication 20180036283A1 · Feb 8, 2018